乳腺癌
癌症研究
免疫抑制
医学
癌症
信号转导
免疫系统
转移
生物
乳腺肿瘤
免疫学
作者
Stefan Mereiter,Gustav Jonsson,Tiago Oliveira,Ingrid Garberis,Johannes Helm,Markus Abeln,Ann-Kristin Jochum,Wolfram Jochum,Max J. Kellner,Marek Feith,Vanessa Tkalec,Karolina Wasilewska,Jie Jiao,David Hoffmann,Lukas Emsenhuber,Felix Holstein,Anna C. Obenauf,Guido Kroemer,Magali Lacroix‐Triki,Omar Hasan Ali
标识
DOI:10.1038/s41467-026-73401-9
摘要
Breast cancer is the most prevalent cancer among women, yet immune checkpoint inhibitors remain largely ineffective in the majority of patients. Here we show that tumor sialylation is negatively associated with T cell infiltration across molecular breast cancer subtypes. In preclinical models, both genetic and pharmacologic inhibition of tumor cell sialylation reshape the tumor microenvironment by reducing immunosuppressive neutrophil infiltration, while CD8⁺ effector and Tcf7⁺ memory T cells are increased within the mammary tumors. Mechanistically, sialylation enhances the serum half-life of granulocyte colony-stimulating factor (G-CSF), a key driver of neutrophilic immunosuppression, and dampens tumor cell immunogenicity by limiting MHC-I surface expression. Disruption of sialylation sensitizes resistant mammary tumors to CD8⁺ T cell-mediated killing and anti-PD-1 therapy in multiple breast cancer models. These findings establish tumor sialylation as a key mechanism of immune evasion and a potential therapeutic target in breast cancer. Tumor sialylation has been associated with different mechanisms of immune evasion. Here the authors show that tumor sialylation regulates G-CSF stability to promote neutrophil-mediated immunosuppression as well dampens tumor cell immunogenicity by limiting MHC-I surface expression, limiting anti-tumor immunity in breast cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI